Animal Models of Breast Cancer
36. McCormick DL, Adamowski CB, Fiks A, Moon RC. Life time dose response relationship for mammary tumor induction by a single administration of MNU. Cancer Res. 1981;41:1690–4.PubMed 37. Thompson HJ,…
ONCOLOGY
Omics of Chemoresistant and Metastatic Breast Cancer
Luminal A Luminal B Basal-like or TNCB HER2/ErbB2 Normal-like Claudin-low Genetic signature Luminal A (estrogen receptor positive and/or progesterone receptor positive, HER2 negative) Luminal B (estrogen receptor positive and/or…
Omics of Male Breast Cancer
BRCA 1 CD105 BRCA 2 Survivin HER2 gene (HER2/neu or ErbB2) COX-2 MYC Ki67 ER Tropomyosins PR NAT1 BRST2 RAD51B (14q24.1) AR TOX3 (16q12.1) C-erb-2 rs13387042 (2q35) p53 rs10941679 (5p12)…
Metabolomics in Breast Cancer
Chemical shift Multiplicity Assignment p-value (pCR vs. SD) p-value (pCR vs. PR) p-value (PR vs. SD) 4.24 m Threonine 0.04 0.28 0.30 1.00 s Isoleucine 0.04 0.01 0.02 2.09 m…
Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer
Gene ID Symbol Function of gene 2064 ERBB2/HER2 Epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Amplification and/or overexpression has been reported in numerous cancers 7153 TOP2A DNA…
Omics Technologies Applied in Breast Cancer Research
Fig. 1.1 Relationship between gene, DNA, RNA, and protein (the central dogma of molecular biology) with omics technologies Genomics Genomics may be described as the comprehensive analysis of genes and…
Nutrigenomics in Breast Cancer
Fig. 6.1 Bioactive food components and its integration with various molecular streams in phenotype progression and development Table 6.1 Factors affecting nutrigenomic research and phenotype Approach Definition and factors Transcriptomics…
Epigenomics of Breast Cancer
Gene (description) Function Sample obtained Case # Methy. status Marker Reference 14-3-3-σ/stratifin (SFN) Cell cycle regulation Cell lines, tissue 20 Hyper Therapeutic Ferguson et al. [202] 14-3-3-σ/stratifin (SFN)å Cell cycle…
Magnetic Nanostructures (MNS) for Cancer
Fig. 1 Size scale of MNS as compared to biomolecules. MNS can be adapted to include biomolecules, drugs, or targeting and imaging molecules to form targeted MNS theranostic agents Typically, MNS…
the Nanoparticle-Protein Interface for Cancer Therapeutics
Forces Strength Range (nm)* Specificity Main factors vdw forces Weak 0–10 No Interface complementarity H-bond Moderate <0 Partial Hydrogen donor/acceptor at interface Electrostatic forces Moderate 0–10 No Charge state, ionic…
